BofA Securities Upgrades Vir Biotechnology (VIR) to Buy, 'Underappreciated HDV opportunity, TCEs essentially free'

BofA Securities analyst Geoff Meacham upgraded Vir Biotechnology (NASDAQ: VIR) from Neutral to Buy with a price target of $14.00 (from $12.00).

The analyst comments "We are upgrading Vir to Buy from Neutral and raising our PO to $14 from $12 as we think the market is underestimating the potential for its asset for treatment of severe liver disease caused by hepatitis delta virus (HDV, >$1B unadjusted peak sales). Further, there seems to be minimal value attributed to T-cell engager (TCE) oncology programs despite initial proof-of-concept data. Having traded -40% YTD on what we view as a lack of catalyst flow and concerns on cash burn, we see two key points driving upside next 12 months: 1) spend for the pivotal ECLIPSE phase 3 trials is warranted in our view given derisking data last year ahead of share-moving pivotal trial readouts in late 2026e and 2) masked TCEs limiting off-target activity may be differentiated from competitors on dosing frequency and efficacy in large cancer types (breast, prostate, colorectal)."

For an analyst ratings summary and ratings history on Vir Biotechnology click here. For more ratings news on Vir Biotechnology click here.

Shares of Vir Biotechnology closed at $4.44 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027